Stock Events

Stock Events

OptiNose 

€8.25
26
+€0+0% Monday 06:52

Statistics

Day High
8.25
Day Low
8.25
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Jun 7
€0.02
Mar 7
€0.02
Dec 6
€0.02
Aug 6
€0.02
Jun 6
€0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
-1.21
-0.8
-0.4
0
Expected EPS
-0.5074375
Actual EPS
N/A

Financials

-27.48%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
72.91MRevenue
-20.04MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0OP0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca competes with OptiNose in the respiratory and allergy medication market, offering alternative treatments.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline offers a range of respiratory products that compete directly with OptiNose's nasal delivery treatments.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.68B
Teva Pharmaceutical Industries has a portfolio of generic and specialty medicines, including nasal sprays for allergies, competing with OptiNose.
Merck
MRK
Mkt Cap276.38B
Merck & Co. provides a variety of healthcare solutions, including treatments for respiratory conditions that compete with OptiNose products.
Pfizer
PFE
Mkt Cap153.59B
Pfizer offers a broad array of drugs, including those for respiratory health, directly competing with OptiNose's market.
Novartis
NVS
Mkt Cap280.79B
Novartis AG, through its generic division Sandoz, and its innovative medicines, competes in the respiratory and nasal drug markets.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson, through its pharmaceutical division, offers products that compete in the same space as OptiNose's treatments.
Abbvie
ABBV
Mkt Cap351.47B
AbbVie competes with OptiNose in the specialty drug market, including treatments for respiratory conditions.
Sanofi
SNY
Mkt Cap112.08B
Sanofi provides a range of treatments for allergies and respiratory conditions, competing with OptiNose's nasal therapy products.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals, known for its innovative treatments, competes in the allergy and respiratory market, affecting OptiNose's position.

About

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Show more...
CEO
Dr. Ramy A. Mahmoud M.D., M.P.H.
Employees
127
Country
United States
ISIN
US68404V2097
WKN
000A40XND

Listings

0 Comments

Share your thoughts

FAQ

What is OptiNose stock price today?▼
The current price of 0OP0.F is €8.25 EUR — it has increased by +0% in the past 24 hours. Watch OptiNose stock price performance more closely on the chart.
What is OptiNose stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange OptiNose stocks are traded under the ticker 0OP0.F.
What is OptiNose revenue for the last year?▼
OptiNose revenue for the last year amounts to 72.91M EUR.
What is OptiNose net income for the last year?▼
0OP0.F net income for the last year is -20.04M EUR.
Does OptiNose pay dividends?▼
Yes, 0OP0.F dividends are paid quarterly. The last dividend per share was 0.02 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does OptiNose have?▼
As of April 29, 2026, the company has 127 employees.
In which sector is OptiNose located?▼
OptiNose operates in the Health & Wellness sector.
When did OptiNose complete a stock split?▼
The last stock split for OptiNose was on December 31, 2024 with a ratio of 1:15.
Where is OptiNose headquartered?▼
OptiNose is headquartered in Yardley, United States.